Egalet Corporation (EGLT) 6.20 $EGLT
Egalet President and CEO Bob Radie Named EY Entrepreneur of the Year®
PR Newswire - Fri Jun 10, 5:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that president and chief executive officer Bob Radie has been named the Greater Philadelphia's 2016 EY Entrepreneur of the Year® in healthcare.
EGLT: 6.20 (-0.07)
Egalet Settles Patent Litigations with Purdue Pharma
PR Newswire - Mon May 23, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that it has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for OXAYDO® (oxycodone HCl, USP) tablets CII. In April 2015 and April 2016 Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. filed patent infringement lawsuits against Egalet for OXAYDO alleging the product infringes Purdue's U.S. Patent No. 8,389,007 and U.S. Patent No. 9,308,171, respectively. Purdue has agreed to dismiss the complaints and both parties have agreed not to pursue any further action on OXAYDO, an immediate-release opioid product. There are no financial obligations to either party.
EGLT: 6.20 (-0.07), ACUR: 1.91 (-0.47)
Egalet Human Abuse Potential Data at American Pain Society Annual Meeting Demonstrates Significantly Lower Intranasal Abuse Potential of ARYMO(TM) ER Compared to MS Contin®
PR Newswire - Thu May 12, 7:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, presented data at the 35th Annual American Pain Society annual meeting demonstrating that ARYMO(TM) ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate, had significantly lower drug liking scores compared to MS Contin® (morphine sulfate extended-release tablets) CII. The Category 2/3 intranasal human abuse potential (HAP) study showed no relevant food effect with ARYMO ER, while an in vitro dissolution study showed no evidence of alcohol dose dumping. Developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, ARYMO ER was created using Egalet's proprietary Guardian(TM) Technology. The U.S. Food and Drug Administration (FDA) accepted the new drug application (NDA) for ARYMO ER and it is currently under review. The FDA Prescription Drug User Fee Act (PDUFA) goal date for a decision on ARYMO ER is October 14, 2016.
EGLT: 6.20 (-0.07)
Egalet reports 1Q loss
Automated Insights - Tue May 10, 5:22AM CDT
WAYNE, Pa. (AP) _ Egalet Corp. (EGLT) on Tuesday reported a loss of $18.5 million in its first quarter.
EGLT: 6.20 (-0.07)
Egalet Announces Scientific Presentations at American Pain Society Meeting
PR Newswire - Thu May 05, 5:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that researchers will present three scientific posters at the 35th Annual American Pain Society meeting May 11 to 14, 2016 in Austin, TX for ARYMO(TM) ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate.
EGLT: 6.20 (-0.07)
Egalet to Present at Upcoming Investor Conferences this Spring
PR Newswire - Wed May 04, 3:30PM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" , a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that the company is scheduled to present at three upcoming conferences this Spring. Egalet will provide an update on marketed products, SPRIX® (ketorolac tromethamine) Nasal Spray and OXAYDO® (oxycodone HCI, USP) tablets for oral use only -CII, as well as and Guardian(TM) Technology product candidates ARYMO(TM) ER, an abuse-deterrent, extended release morphine, and Egalet-002, an abuse-deterrent, extended-release oxycodone. The presentations are as follows:
EGLT: 6.20 (-0.07)
Acura Pharmaceuticals Announces First Quarter 2016 Financial Results
Marketwired - Mon May 02, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016.
EGLT: 6.20 (-0.07), ACUR: 1.91 (-0.47)
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on May 10, 2016
PR Newswire - Wed Apr 27, 5:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that its first quarter financial results will be released on Tuesday, May 10, 2016. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the company's financial and operating results and provide a general business update.
EGLT: 6.20 (-0.07)
Egalet Announces Upcoming Opportunities for Community to Dispose of Prescription Medications
PR Newswire - Thu Apr 21, 3:30PM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today two upcoming prescription drug take-back days to provide a safe, convenient and responsible means of disposing of prescription drugs.
EGLT: 6.20 (-0.07)
Egalet Announces ALERRT(SM) Study Demonstrated Egalet-002 Required Significantly More Effort to Manipulate than OxyContin®
PR Newswire - Thu Mar 24, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" , a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced positive top-line results from a study using the ALERRT instrument. The study showed that Egalet-002, an abuse-deterrent, extended-release oxycodone product candidate which uses Egalet's Guardian(TM) Technology, required significantly more effort to manipulate than OxyContin (oxycodone hydrochloride). The ALERRT instrument, which uses visual analog scales, is a tool developed by PinneyAssociates, Inc. to standardize how to quantify the level of effort required to manipulate an abuse-deterrent product candidate. The study was conducted in accordance with the U.S. Food and Drug Administration's (FDA) final Guidance for Industry, Abuse-Deterrent Opioids -- Evaluation and Labeling (April, 2015), which states that "testing should provide information sufficient to fully characterize the product's abuse-deterrent properties, including the degree of effort required to bypass or defeat those properties."
EGLT: 6.20 (-0.07)
Egalet Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Mar 08, 5:00AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet" , a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today reported financial results for the fourth quarter and year ended December 31, 2015.
EGLT: 6.20 (-0.07)
Capella Bioscience Completes Series A Financing of GBP11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire Europe - Tue Mar 08, 3:01AM CST
LONDON, March 8, 2016 /PRNewswire/ --
VSAR: 10.74 (-0.04), EGLT: 6.20 (-0.07), NERV: 10.36 (+0.07)
Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire - Tue Mar 08, 3:00AM CST
Capella Bioscience Ltd. announced today the close of a £11 million ($15.5 million), Series A financing round. The round was financed by Advent Life Sciences, Medicxi Ventures, and Osage University Partners. The new capital will support continued advancement of the company's novel therapeutic antibody discovery programs towards clinical evaluation.
VSAR: 10.74 (-0.04), EGLT: 6.20 (-0.07), NERV: 10.36 (+0.07)
Egalet to Present at BIO CEO & Investor Conference
PR Newswire - Tue Feb 09, 5:00AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet" , a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that Bob Radie, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference in New York. The presentation will be today, Tuesday, February 9 at 4:00 PM. To view the webcast, please visit the website at http://egalet.investorroom.com/.
EGLT: 6.20 (-0.07)
Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.69 (-0.16), COLL: 15.88 (-0.61), LLY: 73.51 (-0.92), AGN: 244.17 (-3.23), JNJ: 116.55 (-0.45), INSY: 14.96 (-1.07), EGLT: 6.20 (-0.07), ACAD: 39.48 (-0.73), CLCD: 6.53 (-0.27), HRTX: 19.48 (-0.11), AZN: 28.09 (-0.87), ABBV: 60.35 (-0.40), PTIE: 2.21 (unch)
Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a EUR210m Fund including GSK and Johnson & Johnson Innovation
PR Newswire Europe - Tue Feb 02, 12:01AM CST
LONDON, GENEVA and JERSEY, February 2, 2016 /PRNewswire/ --
VSAR: 10.74 (-0.04), EGLT: 6.20 (-0.07), NERV: 10.36 (+0.07)
Egalet President and CEO Bob Radie Named EY Entrepreneur of the Year®
PR Newswire - Fri Jun 10, 5:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that president and chief executive officer Bob Radie has been named the Greater Philadelphia's 2016 EY Entrepreneur of the Year® in healthcare.
EGLT: 6.20 (-0.07)
Egalet Settles Patent Litigations with Purdue Pharma
PR Newswire - Mon May 23, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that it has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for OXAYDO® (oxycodone HCl, USP) tablets CII. In April 2015 and April 2016 Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. filed patent infringement lawsuits against Egalet for OXAYDO alleging the product infringes Purdue's U.S. Patent No. 8,389,007 and U.S. Patent No. 9,308,171, respectively. Purdue has agreed to dismiss the complaints and both parties have agreed not to pursue any further action on OXAYDO, an immediate-release opioid product. There are no financial obligations to either party. EGLT: 6.20 (-0.07), ACUR: 1.91 (-0.47)
Egalet Human Abuse Potential Data at American Pain Society Annual Meeting Demonstrates Significantly Lower Intranasal Abuse Potential of ARYMO(TM) ER Compared to MS Contin®
PR Newswire - Thu May 12, 7:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, presented data at the 35th Annual American Pain Society annual meeting demonstrating that ARYMO(TM) ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate, had significantly lower drug liking scores compared to MS Contin® (morphine sulfate extended-release tablets) CII. The Category 2/3 intranasal human abuse potential (HAP) study showed no relevant food effect with ARYMO ER, while an in vitro dissolution study showed no evidence of alcohol dose dumping. Developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, ARYMO ER was created using Egalet's proprietary Guardian(TM) Technology. The U.S. Food and Drug Administration (FDA) accepted the new drug application (NDA) for ARYMO ER and it is currently under review. The FDA Prescription Drug User Fee Act (PDUFA) goal date for a decision on ARYMO ER is October 14, 2016.
EGLT: 6.20 (-0.07)
Egalet reports 1Q loss
Automated Insights - Tue May 10, 5:22AM CDT
WAYNE, Pa. (AP) _ Egalet Corp. (EGLT) on Tuesday reported a loss of $18.5 million in its first quarter.
EGLT: 6.20 (-0.07)
Egalet Announces Scientific Presentations at American Pain Society Meeting
PR Newswire - Thu May 05, 5:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that researchers will present three scientific posters at the 35th Annual American Pain Society meeting May 11 to 14, 2016 in Austin, TX for ARYMO(TM) ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate.
EGLT: 6.20 (-0.07)
Egalet to Present at Upcoming Investor Conferences this Spring
PR Newswire - Wed May 04, 3:30PM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that the company is scheduled to present at three upcoming conferences this Spring. Egalet will provide an update on marketed products, SPRIX® (ketorolac tromethamine) Nasal Spray and OXAYDO® (oxycodone HCI, USP) tablets for oral use only -CII, as well as and Guardian(TM) Technology product candidates ARYMO(TM) ER, an abuse-deterrent, extended release morphine, and Egalet-002, an abuse-deterrent, extended-release oxycodone. The presentations are as follows: EGLT: 6.20 (-0.07)
Acura Pharmaceuticals Announces First Quarter 2016 Financial Results
Marketwired - Mon May 02, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016.
EGLT: 6.20 (-0.07), ACUR: 1.91 (-0.47)
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on May 10, 2016
PR Newswire - Wed Apr 27, 5:00AM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that its first quarter financial results will be released on Tuesday, May 10, 2016. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the company's financial and operating results and provide a general business update.
EGLT: 6.20 (-0.07)
Egalet Announces Upcoming Opportunities for Community to Dispose of Prescription Medications
PR Newswire - Thu Apr 21, 3:30PM CDT
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today two upcoming prescription drug take-back days to provide a safe, convenient and responsible means of disposing of prescription drugs.
EGLT: 6.20 (-0.07)
Egalet Announces ALERRT(SM) Study Demonstrated Egalet-002 Required Significantly More Effort to Manipulate than OxyContin®
PR Newswire - Thu Mar 24, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced positive top-line results from a study using the ALERRT instrument. The study showed that Egalet-002, an abuse-deterrent, extended-release oxycodone product candidate which uses Egalet's Guardian(TM) Technology, required significantly more effort to manipulate than OxyContin (oxycodone hydrochloride). The ALERRT instrument, which uses visual analog scales, is a tool developed by PinneyAssociates, Inc. to standardize how to quantify the level of effort required to manipulate an abuse-deterrent product candidate. The study was conducted in accordance with the U.S. Food and Drug Administration's (FDA) final Guidance for Industry, Abuse-Deterrent Opioids -- Evaluation and Labeling (April, 2015), which states that "testing should provide information sufficient to fully characterize the product's abuse-deterrent properties, including the degree of effort required to bypass or defeat those properties." EGLT: 6.20 (-0.07)
Egalet Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Mar 08, 5:00AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today reported financial results for the fourth quarter and year ended December 31, 2015. EGLT: 6.20 (-0.07)
Capella Bioscience Completes Series A Financing of GBP11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire Europe - Tue Mar 08, 3:01AM CST
LONDON, March 8, 2016 /PRNewswire/ --
VSAR: 10.74 (-0.04), EGLT: 6.20 (-0.07), NERV: 10.36 (+0.07)
Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire - Tue Mar 08, 3:00AM CST
Capella Bioscience Ltd. announced today the close of a £11 million ($15.5 million), Series A financing round. The round was financed by Advent Life Sciences, Medicxi Ventures, and Osage University Partners. The new capital will support continued advancement of the company's novel therapeutic antibody discovery programs towards clinical evaluation.
VSAR: 10.74 (-0.04), EGLT: 6.20 (-0.07), NERV: 10.36 (+0.07)
Egalet to Present at BIO CEO & Investor Conference
PR Newswire - Tue Feb 09, 5:00AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that Bob Radie, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference in New York. The presentation will be today, Tuesday, February 9 at 4:00 PM. To view the webcast, please visit the website at http://egalet.investorroom.com/. EGLT: 6.20 (-0.07)
Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.69 (-0.16), COLL: 15.88 (-0.61), LLY: 73.51 (-0.92), AGN: 244.17 (-3.23), JNJ: 116.55 (-0.45), INSY: 14.96 (-1.07), EGLT: 6.20 (-0.07), ACAD: 39.48 (-0.73), CLCD: 6.53 (-0.27), HRTX: 19.48 (-0.11), AZN: 28.09 (-0.87), ABBV: 60.35 (-0.40), PTIE: 2.21 (unch)
Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a EUR210m Fund including GSK and Johnson & Johnson Innovation
PR Newswire Europe - Tue Feb 02, 12:01AM CST
LONDON, GENEVA and JERSEY, February 2, 2016 /PRNewswire/ --
VSAR: 10.74 (-0.04), EGLT: 6.20 (-0.07), NERV: 10.36 (+0.07)
